While Morgan Stanley analyst Erik Woodring sees China confrontation risks unlocking the bear case for the stock, he remained positive due to “several mitigation efforts at play.”
The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78 million.
RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise.
CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.
Raymond James said the company’s wireless growth and free cash flow ramp will attract investors, while Citi views that the stock valuation has partly factored in improvement in fundamentals.
The company said that the official declaration of the cash dividend will be subject to the approval of Aerovate board of directors and is expected to be announced later this month.
Donald Trump’s sweeping tariffs, announced last week, have added pressure to an already soft business, weighed down by intense competition and weak consumer spending.
Building a strong investment portfolio requires an allocation for growth, one for stability, and a last one for income, especially when it comes to planning for retirement.
H.C. Wainwright told investors in a research note that the clinical hold on key Elevidys trials in Europe heightens the uncertainty around the future of the franchise.
Company CEO Gary Delanois said that the company is “rapidly evolving” from its traditional leasing model to a direct provider of radiation therapy treatment services to cancer patients.
